Company-Sponsored Scientific Publications on Opioid Overdose Reversal

Time Course of Reversal of Fentanyl Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone.

J Clin Pharmacol. 2025;65(2):206-216.

Cipriano A, Apseloff G, Kapil RP, He E, Shet M, Harris SC.

Development of a Sensitive Method for the Detection and Quantitation of Nalmefene in Human Plasma Samples for Pharmacokinetic Analysis.

Abstract presented at American Association of Pharmaceutical Scientists annual meeting.

Bennett D, Chinnici C, Williard C, Shet MS.

Development of a Nalmefene Formulation Suitable for a Community-Use Auto-Injector. 

Br J Clin Pharmacol. 2026; 1-12.

Cipriano A, Shet MS, Huang H, et al. 

Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal Naloxone.

J Clin Pharmacol. 2025;65(12):1661-1675.

Cipriano A, He E, Shet M, Apseloff G, Harris SC.  

Laypeople Express a Willingness and Comfort to Use Autoinjectors as an Option for Reversing the Symptoms of Opioid Overdoses.

American Journal of Health-System Pharmacy, 2025 ASHP Midyear Clinical Meeting Poster Abstracts, Volume 83, Issue Supplement_2, 6 March 2026.

Alfieri T, Erensen J.

Use of Multiple Naloxone Administrations in the Emergency Department: A Retrospective Claims-Based Analysis.

J Emerg Med. 2025;79:111-122.

Rzasa Lynn R, Galinkin J, McClain M, Alfieri T.